1-20 of 85
Fritz Offner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raul Cordoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Kimberly G. Archer, Ali Rana, David Belada
Journal: Blood
Blood (2024) 144 (Supplement 1): 581.
https://doi.org/10.1182/blood-2024-198023
Published: 2024
Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Martin Hutchings, Michael J. Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, William Townsend, Francesc Bosch, Nancy L. Bartlett, Guillaume Cartron, Herve Ghesquieres, Roch Houot, Harriet S. Walter, Fritz Offner, Natalie Dimier, Candice Jamois, Lance Smith, Sylvia Herter, Denis Sahin, Abiraj Keelara, Koorosh Korfi, Jeremy Gallien, Marie-Helene Wasmer, Heather Hinton, Matt Whayman, Isabel Prieto, Georgios Kazantzidis, Katharina Lechner, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 990.
https://doi.org/10.1182/blood-2024-200096
Published: 2024
Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Tycel J. Phillips, Marek Trněný, Carmelo Carlo-Stella, Jan Maciej Zaucha, Tomasz Wrobel, Fritz Offner, Michael J. Dickinson, Monica Tani, Michael Crump, Nancy L. Bartlett, Joaquín Martínez-Lopez, Paolo Corradini, Estefania Mulvihill, Alessia Bottos, Derrick Kaufman, James Relf, Fabiola Bene Tchaleu, Alexandra Bazeos, Linda Lundberg, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 1631.
https://doi.org/10.1182/blood-2024-200018
Published: 2024
Journal Articles

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Joshua Brody, Lorenzo Falchi, Umberto Vitolo, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Poliana Patah, Jennifer Marek, Christopher Morehouse, Andrew J. Steele, Yi Hao, Daniela Hoehn, Kim Linton
Journal: Blood
Blood (2024) 144 (Supplement 1): 1627.
https://doi.org/10.1182/blood-2024-200369
Published: 2024
Journal Articles

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Philippe Decruyenaere, Daniela Drandi, Kimberly Verniers, Simone Ragaini, Jasper Anckaert, Veronica Peri, Elisa Genuardi, Federica Cavallo, Luigi Marcheselli, Irene Dogliotti, Emanuele Cencini, Dario Marino, Angela Ferrari, Simona Tomassetti, Luca Laurenti, Giacomo Loseto, Monia Marchetti, Annelien Morlion, Ramon García-Sanz, Fritz Offner, Benedetto Bruno, Marzia Varettoni, Jo Vandesompele, Simone Ferrero
Journal: Blood
Blood (2024) 144 (Supplement 1): 3297.
https://doi.org/10.1182/blood-2024-198382
Published: 2024
Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Uwe Hahn, Nancy L. Bartlett, Jeong-A Kim, Krimo Bouabdallah, Nicholas Forward, Tsai-Yun Chen, Vincent Camus, Ming-Chung Wang, Philippe Carassou, Enrico Derenzini, Hung Chang, Fritz Offner, Herve Ghesquieres, Grzegorz S. Nowakowski, Christopher Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Craig A. Portell
Journal: Blood
Blood (2024) 144 (Supplement 1): 4489.
https://doi.org/10.1182/blood-2024-200914
Published: 2024
Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Catherine Thieblemont, Martin Dreyling, Michael J. Dickinson, Joaquín Martínez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, Phoebe Joy Ho, Jose Antonio Pérez-Simón, Andy Chen, Loretta Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E.M. Patten, Joseph P. McGuirk, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Davide Germano, Roberto Javier Ramos, Pei Hsu, Stephen J. Schuster, Nathan H. Fowler
Journal: Blood
Blood (2024) 144 (Supplement 1): 3034.
https://doi.org/10.1182/blood-2024-201730
Published: 2024
Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Alexey Danilov, Bita Fakhri, Farrukh T. Awan, Hans Herluf Bentzen, Herbert A. Eradat, Carsten Utoft Niemann, Fritz Offner, Christian Bjørn Poulsen, Thor Hoeyer, Mar Bellido, Damien Roos Weil, Alessandra Ferrajoli, Meghan C. Thompson, Jacob Haaber Christensen, Ann Janssens, Tamar Tadmor, Mazyar Shadman, Pegah Jafarinasabian, Jimin Zhang, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 883.
https://doi.org/10.1182/blood-2024-199708
Published: 2024
Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Clinical Trials & Observations
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez-Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thieblemont, Stephen J. Schuster
Journal: Blood
Blood (2024) 143 (17): 1713–1725.
https://doi.org/10.1182/blood.2023021567
Published: 2024
Includes: Supplemental data
Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Koorosh Korfi, Ailsa Christiansen, Zhiwen Jiang, Sabine Wilson, Samuel Tracy, Annika Blank, Sylvia Herter, Natalie Dimier, Bruno Gomes, Pablo Umana, Herve Ghesquieres, Roch Houot, Fritz Offner, Harriet Walter, Nancy L. Bartlett, Guillaume Cartron, Michael Dickinson, William Townsend, Giuseppe Gritti, Francesc Bosch Albareda, Franck Morschhauser, Martin Hutchings, Carmelo Carlo-Stella, Katharina Lechner
Journal: Blood
Blood (2023) 142 (Supplement 1): 3017.
https://doi.org/10.1182/blood-2023-173677
Published: 2023
Journal Articles

Real-World Effectiveness and Safety of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) in Belgium after 4 Years

Kirsten Saevels, Sylvia Snauwaert, Gaeten Vanstralen, Marc Andre, Fritz Offner, Ariane Maes, Marjolein Lahaye, Ann Janssens
Journal: Blood
Blood (2023) 142 (Supplement 1): 6550.
https://doi.org/10.1182/blood-2023-174762
Published: 2023
Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Stephen J Schuster, Nathan Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A Riedell, Phoebe Joy Ho, Jose A. Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers Patten, Joseph P McGuirk, Andreas L Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Ines Paule, Davide Germano, Roberto Javier Ramos, Pei Hsu, Catherine Thieblemont, Martin Dreyling
Journal: Blood
Blood (2023) 142 (Supplement 1): 601.
https://doi.org/10.1182/blood-2023-180936
Published: 2023
Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Lorenzo Falchi, Lori A. Leslie, David Belada, Katerina Kopeckova, Fritz Offner, Joshua Brody, Miguel Canales, Alejandro Martín García-Sancho, Marcel Nijland, P-O Andersson, Farrukh T. Awan, Jacob Haaber Christensen, Kristina Drott, Mats Hellström, Catharina Lewerin, Mayur Narkhede, Sylvia Snauwaert, Björn E Wahlin, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, Joost S.P. Vermaat, Pau Abrisqueta
Journal: Blood
Blood (2022) 140 (Supplement 1): 1471–1473.
https://doi.org/10.1182/blood-2022-158232
Published: 2022
Journal Articles

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, Carmelo Carlo-Stella, Giuseppe Gritti, Francesc Bosch, Franck Morschhauser, William Townsend, Fritz Offner, Harriet S Walter, Herve Ghesquieres, Roch Houot, Guillaume Cartron, Natalie Dimier, Stephen Fowler, Emma Harrop, Sylvia Herter, Abiraj Keelara, Koorosh Korfi, Jeff Luong, Claudia Mueller, Robert Nutbrown, Giuseppe Palldino, Matt Whayman, Isabel Prieto, Sarah Louise Mycroft, Daria Rukina, Katharina E Lechner, Michael Dickinson
Journal: Blood
Blood (2022) 140 (Supplement 1): 9461–9463.
https://doi.org/10.1182/blood-2022-157011
Published: 2022
Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 178–180.
https://doi.org/10.1182/blood-2022-157777
Published: 2022
Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips
Journal: Blood
Blood (2022) 140 (Supplement 1): 1068–1069.
https://doi.org/10.1182/blood-2022-158278
Published: 2022
Journal Articles

CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89 Zr-Crefmirlimab Berdoxam

Martin Hutchings, Annika Loft, Wendy Osborne, George Petrides, Fritz Offner, Ciel De Vriendt, Giuseppe Gritti, Roberto Boni, William Townsend, Irfan Kayani, Ian Wilson, Yanjie Wang, Maria Jadhav, Cristina Santini, Claire Kelly, Martin Kornacker, Jean J.L. Tessier, Ann-Marie E Bröske, Angelika Lahr, Axel Boehnke, Christoph M. Griessinger
Journal: Blood
Blood (2022) 140 (Supplement 1): 10733–10735.
https://doi.org/10.1182/blood-2022-158154
Published: 2022
Journal Articles

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

John P. Leonard, Marek Trneny, Fritz Offner, Jiri Mayer, Huilai Zhang, Grzegorz S. Nowakowski, Phillip Scheinberg, Argyrios Gkasiamis, Joanna Mikita-Geoffroy, Everton Rowe, John G. Gribben
Journal: Blood
Blood (2022) 140 (Supplement 1): 561–563.
https://doi.org/10.1182/blood-2022-158631
Published: 2022
Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Martin Hutchings, Caroline Hasselbalch Riley, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10137–10139.
https://doi.org/10.1182/blood-2022-158146
Published: 2022
Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Martin Dreyling, Michael Dickinson, Joaquin Martinez Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, Phoebe Joy Ho, Jose A. Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J M Ferreri, Takanori Teshima, Piers E.M. Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O'Donovan, Roberto Ramos, Aisha Masood, Catherine Thieblemont, Nathan H. Fowler, Stephen J. Schuster
Journal: Blood
Blood (2022) 140 (Supplement 1): 1459–1463.
https://doi.org/10.1182/blood-2022-158024
Published: 2022